Please enter your license information:
- Trajenta® Product Monograph, Boehringer Ingelheim (Canada) Ltd., February 25, 2021.
- Data on file, Boehringer Ingelheim (Canada) Ltd., February 1, 2023.
- Health Canada. Notice of Compliance Information for Trajenta®.
- Januvia® Product Monograph, Merck Canada Inc., July 27, 2021.
- Onglyza® Product Monograph, AstraZeneca Canada Inc., June 29, 2021.
- Data on file: U10-1608-01, Boehringer Ingelheim (Canada) Ltd.
- McGill JB, et al. Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study. Diabetes Care 2013;36(2):237–44.
- Del Prato S, et al. Effect of linagliptin monotherapy on glycemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab 2011;13(3):258–67.
- Taskinen MR, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011;13(1):65–74.
- Gomis R, et al. Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extension. Int J Clin Pract 2012;66(8):731–40.
- Data on file: 1218.15-.18 +.40, Boehringer Ingelheim (Canada) Ltd.
- Rosenstock J, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: The CARMELINA Randomized Clinical Trial. JAMA 2019;321(1):69–79.
- Rosenstock J, et al. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: The CAROLINA Randomized Clinical Trial. JAMA 2019;322(12):1155–66.
- Data on file: 1218-0074, Boehringer Ingelheim (Canada) Ltd., May 25, 2020.
- Jentadueto® Product Monograph, Boehringer Ingelheim (Canada) Ltd., March 5, 2021.
- Government of Alberta. Alberta Health – Drug Benefit List. April 1, 2021. Available at: https://www.ab.bluecross.ca/dbl/pdfs/dbl_full_list.pdf.
- Province of British Columbia. Limited Coverage Drugs – Linagliptin and Linagliptin-metformin. Available at: https://www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/pharmacare/prescribers/limited-coverage-drug-program/limited-coverage-drug-linagliptin-and-linagliptin-metformin.
- Manitoba Drug Benefits and Interchangeability Formulary. Part 3 Exception Drug Status (EDS). April 1, 2023. Available at: https://www.gov.mb.ca/health/mdbif/docs/edsnotice.pdf.
- Government of New Brunswick. New Brunswick Drug Plans Formulary. April 2023. Available at: https://www2.gnb.ca/content/dam/gnb/Departments/h-s/pdf/en/NBDrugPlan/NewBrunswickDrugPlansFormulary.pdf.
- Government of Newfoundland and Labrador. Health and Community Services. Newfoundland and Labrador Special Authorization Drug Products. June 2022. Available at: https://www.gov.nl.ca/hcs/files/Criteria-Jun-2022.pdf.
- Nova Scotia Pharmacare. Appendix III – Criteria for Coverage of Exception Status Drugs. March 2023. Available at: https://novascotia.ca/dhw/pharmacare/documents/Criteria-for-Exception-Status-Coverage.pdf.
- Data on file: Trajenta® Coverage Canada, Boehringer Ingelheim (Canada) Ltd., April 28, 2020.
- Data on file: Jentadueto® Coverage Canada, Boehringer Ingelheim (Canada) Ltd., April 28, 2020.
- Government of Ontario. Drugs Funded by Ontario Drug Benefit (ODB) Program: Formulary Search. Available at: https://www.formulary.health.gov.on.ca/formulary/.
- Government of Prince Edward Island. PEI Pharmacare Formulary. April 2023. Available at: https://www.princeedwardisland.ca/sites/default/files/publications/pei_pharmacare_formulary.pdf.
- Régie de l’assurance maladie du Québec (RAMQ*). List of Medications. November 9, 2022. Available at: https://www.ramq.gouv.qc.ca/sites/default/files/documents/liste-med-2022-11-09_en.pdf.
- Régie de l’assurance maladie du Québec (RAMQ*). Codes des médicaments d’exception. April 13, 2023. Available at: https://www.ramq.gouv.qc.ca/SiteCollectionDocuments/professionnels/medicaments/codes-medicaments-exception/codes_medicaments_exception.pdf.
- Government of Saskatchewan. Saskatchewan Formulary Bulletin. Available at: https://formulary.drugplan.ehealthsask.ca/Bulletins/Bulletin-0210-Feb-2022.pdf.
- Government of Yukon. Yukon Drug Formulary. April 2023. Available at: https://ihs.gov.yk.ca/drugs/.
- Government of Canada. Non-Insured Health Benefits: Drug Benefit List. September 2020. Available at: https://www.sac-isc.gc.ca/DAM/DAM-ISC-SAC/DAM-HLTH/STAGING/texte-text/nihb_benefits-services_drugs_dbl-index_1573154657223_eng.pdf.
* Official Mark of the Régie de l’assurance maladie du Québec.
Are you thinking Trajenta®?
![Healthcare professional and patient Healthcare professional and patient](https://pro.boehringer-ingelheim.com/ca/products/trajenta/images/login-banner-updated.png)
Are you a Canadian
View coverage details for Trajenta® and Jentadueto®
![Map of Canada Map of Canada](https://pro.boehringer-ingelheim.com/ca/products/trajenta/images/check-coverage-icon.png)